Do Longevity Drugs Work? GLP-1s, Rapamycin and NAD+ Explained

No corner of the longevity field generates more excitement, or more confident overstatement, than pharmacology. The idea that a drug might slow ageing itself — not treat a disease but address the underlying process — is genuinely one of the most consequential in medicine. It is also one of the most hyped. GLP-1 receptor agonists, rapamycin and NAD+ boosters dominate the conversation, and the honest position on each is more nuanced than either the enthusiasts or the sceptics allow. This is a sober guide to where the human evidence actually stands.

The crucial distinction

Before any specific drug, one distinction governs everything: the difference between treating a condition and slowing ageing. A drug can be genuinely effective for a disease and tell us little about longevity in healthy people. Much of the excitement blurs this line, extrapolating from a proven medical use, or from striking results in mice, to a promise of extended human healthspan that the evidence does not yet support. Weighing longevity pharmacology means holding that distinction firmly.

GLP-1 receptor agonists

This class — the medications behind the recent transformation in obesity and diabetes treatment — is the most evidenced of the three, precisely because it is grounded in genuine, large-scale clinical use. For appropriate patients, these drugs produce substantial, well-documented effects on weight and metabolic health, with growing evidence of cardiovascular benefit. Because obesity and metabolic dysfunction are major drivers of age-related disease, improving them plausibly improves healthspan. The honest caveats: these are prescription medications with real effects and real considerations, appropriate for specific people under medical supervision, not a casual longevity enhancer for the already healthy. Their story is still being written, and the long-term picture in non-diabetic, non-obese people is far less established than the headlines imply.

Rapamycin

Rapamycin is the molecule that most excites longevity science, because it is among the few interventions that reliably extends lifespan in laboratory animals across species. That is a genuinely important finding. But the leap from mouse lifespan to human healthspan is enormous and unproven. In humans, rapamycin is an established immunosuppressant with a known profile of effects; its use specifically for longevity, including questions of dose and timing, remains experimental and the subject of ongoing research rather than settled practice. It sits squarely in the category where the honest words are we do not know yet — promising enough to take seriously, unproven enough to approach with humility.

NAD+ boosters

NAD+ is a molecule central to cellular energy that declines with age, and precursors that raise its levels — sold widely as supplements — are among the most popular longevity purchases. They do what they claim in a narrow sense: they reliably raise NAD+ levels in the blood. What they have not yet shown is that doing so changes any meaningful human ageing outcome. The gap between raising a molecule and improving health is exactly where caution belongs, and where a great deal of money is currently being spent on hope.

How to think about all of it

The reasonable posture toward longevity pharmacology is neither dismissal nor enthusiasm but disciplined attention. This is the most consequential territory in the field and the fastest-moving; some of what is speculative today may be established in time, and some will fade as resveratrol did. The sensible individual does not build a health strategy on unproven drugs, nor ignore a field that may reshape medicine. Anything in this domain that involves a prescription is a decision for you and a qualified physician, weighed for your specific situation — not a purchase to make on the strength of a headline. And beneath all of it, the fundamentals still do more, today, than any longevity drug has yet been proven to: the least glamorous truth, and the most reliable one.